Euclidean Capital
$440M 13F equity value
11 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Euclidean Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| VEU | VANGUARD INTL EQUITY INDEX F | 3,243,484 | $272M | 61.8% |
| VTV | VANGUARD INDEX FDS | 520,000 | $113M | 25.8% |
| INDA | ISHARES TR | 369,600 | $18M | 4.2% |
| ORIC | ORIC PHARMACEUTICALS INC | 989,410 | $11M | 2.4% |
| TMS | TEAMSHARES INC | 1,099,974 | $9M | 2.1% |
| FHTX | FOGHORN THERAPEUTICS INC | 1,573,761 | $8M | 1.7% |
| PMVP | PMV PHARMACEUTICALS INC | 2,627,643 | $4M | 0.8% |
| ALEC | ALECTOR INC | 1,307,858 | $3M | 0.6% |
| SRZN | SURROZEN INC | 87,696 | $2M | 0.5% |
| TNYA | TENAYA THERAPEUTICS INC | 1,015,705 | $750,708 | 0.2% |
Track Euclidean Capital's 13F portfolio: $440M in reported holdings, 11 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}